Document Type : Original Article
Authors
- . Mahsa Panahi‑Shokouh 1
- . Azadeh Moghaddas 1
- . Shirinsadat Badri 2
- . Saeedeh Jabalameli 1
- . Mahnaz Momenzadeh 1
- . Valiollah Mehrzad 3
- . Farzaneh Ashrafi 3
1 Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Oncology/ Hematology, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Objective: Amphotericin B is an antifungal agent used to treat serious fungal
infections mainly in critically ill patients. Despite its adverse effects including
renal toxicity and electrolyte imbalances, amphotericin B remains one of the best
choices for antifungal treatment. Information from animal studies has provided a
strong scientific basis for the use of pentoxifylline as lowering nephroprotective
agent. The present study was designed to evaluate the efficacy of pentoxifylline in
preventing renal toxicity and electrolytes imbalances induced by amphotericin B.
Methods: This study was conducted as a randomized controlled trial on 44 patients
admitted to Sayyedoshohada Hospital, Isfahan, Iran, from October 2016 to August
2018. Patients were assigned to one of the two groups: Pentoxifylline, 400 mg
twice a day, or matching placebo, from the 1st day of amphotericin B therapy till
minimum of 7 days. All patients’ information including lab data (serum and urine
levels of Mg, Na, and K, serum creatinine level, blood urea nitrogen [BUN] and
urinary creatinine excretion) were gathered at the time of drug initiation and during
the study period. The results were analyzed by SPSS v. 20 software and Repeated
measures test was used to assess the differences between groups Findings: This
study did not show any significant differences between the two groups in terms of
all the assessed variables, including serum and urinary levels of electrolytes, and
creatinine, as well as the number of cases presented acute kidney injury during
the study period. Conclusion: Despite the positive effects of pentoxifylline in
preventing renal complications in previous studies, this study could not show a
definitive result in salt wasting or renal damage induced by amphotericin B. So,
Designing robust studies with more included samples would be valuable.
Keywords
A review. J Chemother 2000;12:463-70.
2. Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: Side
effects and toxicity. Rev Iberoam Micol 2009;26:223‑7.
3. Ulozas E. Amphotericin B-induced nephrotoxicity. Compr
Toxicol 2010;7:347-57.
4. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of
clinical experience. Rev Infect Dis 1990;12:308-29.
5. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The
epidemiology of nephrotoxicity associated with conventional
amphotericin B therapy. Am J Med 2001;111:528-34.
6. Karimzadeh I, Khalili H, Farsaei S, Dashti-Khavidaki S,
Sagheb MM. Role of diuretics and lipid formulations in the
prevention of amphotericin B-induced nephrotoxicity. Eur J Clin
Pharmacol 2013;69:1351-68.
7. Karimzadeh I, Farsaei S, Khalili H, Dashti-Khavidaki S. Are salt
loading and prolonging infusion period effective in prevention of
amphotericin B-induced nephrotoxicity? Expert Opin Drug Saf 2012;11:969-83.
8. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol
1994;30:603-21.
9. Kreth S, Ledderose C, Luchting B, Weis F, Thiel M.
Immunomodulatory properties of pentoxifylline are mediated via
adenosine-dependent pathways. Shock 2010;34:10-6.
10. Heystek HC, Thierry AC, Soulard P, Moulon C.
Phosphodiesterase 4 inhibitors reduce human dendritic cell
inflammatory cytokine production and Th1‑polarizing capacity.
Int Immunol 2003;15:827-35.
11. Nasiri-Toosi Z, Dashti-Khavidaki S, Khalili H,
Lessan‑Pezeshki M. A review of the potential protective effects
of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin
Pharmacol 2013;69:1057-73.
12. Rao KM, Currie MS, McCachren SS, Cohen HJ.
Pentoxifylline and other methyl xanthines inhibit interleukin-2
receptor expression in human lymphocytes. Cell Immunol
1991;135:314-25.
13. Rieckmann P, Weber F, Günther A, Martin S, Bitsch A,
Broocks A, et al. Pentoxifylline, a phosphodiesterase inhibitor,
induces immune deviation in patients with multiple sclerosis.
J Neuroimmunol 1996;64:193-200.
14. Strutz F, Heeg M, Kochsiek T, Siemers G, Zeisberg M, Müller
GA. Effects of pentoxifylline, pentifylline and gamma‑interferon
on proliferation, differentiation, and matrix synthesis of human
renal fibroblasts. Nephrol Dial Transplant 2000;15:1535‑46.
15. Berens KL, Luke DR. Pentoxifylline in the isolated perfused rat
kidney. Transplantation 1990;49:876-9.
16. Sullivan GW, Carper HT, Mandell GL. Pentoxifylline modulates
activation of human neutrophils by amphotericin B in vitro.
Antimicrob Agents Chemother 1992;36:408-16.
17. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR,
et al. Correlates of acute renal failure in patients receiving
parenteral amphotericin B. Kidney Int 2001;60:1452-9.
18. Tolins JP, Raij L. Chronic amphotericin B nephrotoxicity in the
rat: Protective effect of calcium channel blockade. J Am Soc
Nephrol 1991;2:98-102.
19. Karimzadeh I, Khalili H, Dashti‑Khavidaki S, Sharifian R,
Abdollahi A, Hasibi M, et al. N-acetyl cysteine in prevention
of amphotericin-induced electrolytes imbalances: A randomized,
double-blinded, placebo-controlled, clinical trial. Eur J Clin
Pharmacol 2014;70:399-408.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D.
A more accurate method to estimate glomerular filtration rate
from serum creatinine: A new prediction equation. Modification
of Diet in Renal Disease Study Group. Ann Intern Med
1999;130(6):461-70.
21. Kidney Disease: Improving Global Outcomes (KDIGO) Acute
Kidney Injury Work Group. KDIGO Clinical Practice Guideline
for Acute Kidney Injury. Kidney Int Suppl 2012;2:1.
22. Lin SL, Chen YM, Chiang WC, Tsai TJ, Chen WY.
Pentoxifylline: A potential therapy for chronic kidney disease.
Nephrology (Carlton) 2004;9(4):198-204.
23. Lin SL, Chiang WC, Chen YM, Lai CF, Tsai TJ, Hsieh BS.
The renoprotective potential of pentoxifylline in chronic kidney
disease. J Chin Med Assoc 2005;68(3):99-105.
24. Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ. Pentoxifylline
ameliorates proteinuria through suppression of renal monocyte
chemo-attractant protein-1 in patients with proteinuric primary
glomerular diseases. Kidney Int 2006;69(8):1410-5.
25. Luke DR, Wasan KM, McQueen TJ, Lopez-Berestein G.
Enhancement of the treatment of experimental candidiasis
with vascular decongestants. Journal of Infectious Diseases
1990;162(1):211-4.
26. Wasan K, Vadiei K, Lopez-Berestein G, Verani R, Luke D.
Pentoxifylline in amphotericin B toxicity rat model.
Antimicrobial agents and chemotherapy 1990;34(2):241-4.
27. Galindo-Rodríguez G, Bustamante R, Esquivel-Nava G,
Salazar‑Exaire D, Vela‑Ojeda J, Vadillo‑Buenfil M, et al.
Pentoxifylline in the treatment of refractory nephrotic syndrome
secondary to lupus nephritis. J Rheumatol 2003;30:2382-4.
28. Badri S, Dashti-Khavidaki S, Ahmadi F, Mahdavi-Mazdeh M,
Abbasi MR, Khalili H. Effect of add‑on pentoxifylline on
proteinuria in membranous glomerulonephritis: A 6-month
placebo-controlled trial. Clin Drug Investig 2013;33:215-22.
29. Mayer J, Doubek M, Doubek J, Horký D, Scheer P, Stepánek M.
Reduced nephrotoxicity of conventional amphotericin B therapy
after minimal nephroprotective measures: Animal experiments
and clinical study. J Infect Dis 2002;186:379-88.
)